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In a systematic analysis of global gene-expression patterns, we found that SOCS3 messenger RNA was signiﬁcantly
more highly expressed in skin from patients with atopic dermatitis than in skin from healthy controls, and im-
munohistochemical analysis conﬁrmed a similar elevation of SOCS3 protein. Furthermore, we found a genetic
association between atopic dermatitis and a haplotype in the SOCS3 gene in two independent groups of patients
( and ). These results strongly suggest that SOCS3, located in a chromosomal region previouslyP ! .02 P ! .03
linked to the disease (17q25), is a susceptibility gene for atopic dermatitis.
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Atopic dermatitis (AD [MIM 603165]), also known as
“eczema” according to the new World Allergy Organi-
zation nomenclature,1 commonly begins in infancy or
early childhood and is characterized by itchy and in-
ﬂamed skin. AD affects 10%–20% of children in West-
ern societies and shows a strong familial aggregation.2
Several genetic linkage and association studies have
sought the underlying genetic causes of AD, and a num-
ber of different chromosomal regions have been impli-
cated by these studies.2–5 In a Swedish population with
AD, a previous genomewide linkage analysis4 showed
suggestive linkage ( ) to susceptibility loci4P ! 7.4# 10
on chromosomes 3, 13, 15, 17, and 18.
Yet very little is known about speciﬁc genes involved
in the pathogenesis of AD. To search systematically for
gene-expression patterns associated with AD, we re-
cently adopted a genomewide approach, using human
cDNA microarrays (M. Bradley, P. O. Brown, H. Y.
Chang, M. Nordenskjo¨ld, A. Scheynius, A. Sa¨a¨f, and M.
Tengvall-Linder, unpublished data). Nine adult patients
with AD were collected at the Dermatology Unit, De-
partment of Medicine, Karolinska University Hospital
Solna, Stockholm. From each individual, two punch bi-
opsy specimens were taken: one from lesional skin and
one from noninvolved PBS-patch-tested skin on the
back. AD was diagnosed using the U.K. Working Party’s
diagnostic criteria.6 The patients had not received treat-
ment for the previous 2 mo and were considered by a
dermatologist to be moderately to severely affected with
AD. For controls, we used four healthy individuals from
the Stockholm area. Two punch biopsy specimens were
taken from the back: one from normal skin and one
from PBS-patch-tested skin. Each punch biopsy speci-
men provided 10–30 mg of total RNA. All patients with
AD had allergen-speciﬁc IgE antibodies, which were not
present in any of the controls.
We used human cDNAmicroarrays containing 41,792
elements representing ∼24,500 unique genes (based on
UniGene clusters) that were manufactured by the Stan-
ford Functional Genomics Facility. Fluorescently labeled
cDNA prepared from ampliﬁed RNA was hybridized to
the array in a two-color comparative format, with sam-
ples from patients with AD and healthy controls labeled
with Cy5 (red) and with a reference pool of human
mRNAs (Stratagene) derived from 10 cell lines labeled
with Cy3 (green). Data were normalized and retrieved
as the log2 ratio of ﬂuorescence intensities of the sample
and the reference.
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Figure 1 SOCS3 mRNA levels in skin from patients with AD
and healthy controls, measured by cDNA microarray. We analyzed
lesional skin and noninvolved PBS-patch-tested skin frompatientswith
AD and normal skin and PBS-patch-tested skin from healthy controls.
The results are displayed as the mean values of all measured SOCS3
mRNA levels for patients and controls in each group (e.g., mean values
of seven lesional and six PBS-patch-tested skin samples from patients
with AD and four normal skin and four PBS-patch-tested skin samples
from controls). SE is indicated for each group. We found that SOCS3
mRNA levels were signiﬁcantly more highly expressed in skin from
patients with AD than in skin from healthy controls. R/Gp red/green.
Table 1
SOCS3 Microarray Data
SKIN SAMPLE
SOCS3 SEQUENCE
GENBANK ACCESSION NUMBER
AA001218 AI922872 T72915
AD lesional skin:
ADL1 .87 .01 .98
ADL2 2.43 2.42 2.18
ADL3 2.48 2.32 2.43
ADL4 .77 .74 .72
ADL5 .36 .42 .61
ADL6 1.16 1.36 2.13
ADL7 .47 .54 .52
AD PBS skina:
ADP1 .84 .04 .12
ADP2 .62 .37 .58
ADP3 NA .38 .45
ADP4 .79 .33 .47
ADP5 .5 .41 .07
ADP6 .88 .64 .69
Control normal skin:
CN1 .43 .85 .72
CN2 NA .95 1.32
CN3 NA .95 1.14
CN4 NA .41 .78
Control PBS skina:
CP1 .91 1.04 .86
CP2 .73 1.14 1.16
CP3 .21 .72 .77
CP4 .42 .75 .62
NOTE.—Data are log2 of red/green normalized ratio. NAp not
available.
a PBS-patch-tested skin.
In analyzing the microarray data by use of the sig-
niﬁcance-analysis-of-microarrays (SAM) algorithm,7 we
found ∼5,000 genes consistently differentially expressed
between skin from patients with AD and skin from con-
trol individuals, with a false-discovery rate !0.7%. The
genomewide portrait of AD will be presented elsewhere
(M. Bradley, P. O. Brown, H. Y. Chang, M. Norden-
skjo¨ld, A. Scheynius, A. Sa¨a¨f, and M. Tengvall-Linder,
unpublished data). Among all the differentially ex-
pressed genes, we focused speciﬁcally on genes located
within chromosomal regions previously linked to AD.
The SOCS3 gene (Locus Link ID 9021; NCBI accession
number NM_003955; UniGene cluster ID Hs.527973),
located in chromosome region 17q25, was found to be
signiﬁcantly more highly expressed in skin from patients
with AD than in skin from healthy individuals (P !
, corrected for multiple testing) (table 1 and ﬁg. 1)..03
SOCS3 is a member of the suppressors of cytokine
signaling (SOCS) family of proteins that act as negative
regulators of cytokine signaling. SOCS proteins interfere
with the binding of cytokine receptors and with intra-
cellular molecules that act downstream. Several studies
have pointed to SOCS proteins as an effective block of
the Janus kinase–signal transducer and activator of tran-
scription (JAK-STAT) pathway in the pathogenesis of
various inﬂammatory diseases.8 Furthermore, Seki et al.8
have reported that patients with AD show signiﬁcantly
increased SOCS3 expression ( ) in peripheralP ! .001
CD3 T cells. On the basis of the microarray results and
the previously described role of SOCS3 in various in-
ﬂammatory diseases, we considered SOCS3 to be a can-
didate gene for AD.
To explore the link between mRNA levels and protein
expression of SOCS3 in AD, we used immunohisto-
chemistry. For this assessment, 15 adult patients with
AD were collected at the Dermatology Unit, Department
of Medicine, Karolinska University Hospital Solna,
Stockholm. They were classiﬁed as having AD on the
basis of the U.K. Working Party’s diagnostic criteria.6
Two punch biopsy specimen from the trunk were taken
from each individual: one from lesional skin and one
from noninvolved skin. Eight healthy adult controls
were collected from the Stockholm area, and biopsy
specimens were taken from normal skin.
Biopsy specimens were snap frozen on dry ice and
were stored at 80C. Six-micrometers-thick cryo sec-
tions were prepared and put on glass slides, ﬁxed in
acetone, and were used in the ABC-ELITE (Vector Lab-
oratories) immunohistochemical staining method. The
sections were treated with 0.3% H2O2 to block endog-
enous peroxidase activity, were incubated with normal
goat serum (dilution 1/10), and were blockedwith avidin
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Figure 2 SOCS3 protein expression (arrows) in lesional skin (A) and nonlesional skin (B) from patients with AD and in normal skin
from healthy controls (C). We found a higher expression of SOCS3 in dendritic cells and an increased number of SOCS3-positive cells in lesional
AD skin (median 5.6 cells/mm; range 1.1–10.5 cells/mm) compared with nonlesional AD skin (median 1.1 cells/mm; range 0–5.6 cells/mm;
) and normal skin (median 0.8 cells/mm; range 0–5.9 cells/mm; ). Frozen skin biopsy specimens were stained with antibodiesP ! .043 P ! .00079
to SOCS3 (dilution 1/250). Scale bar p 50 mm. Statistical tests used were the Wilcoxon matched-pairs test and Mann-Whitney U test.
and biotin (Vector Laboratories). A mouse monoclonal
antibody against human SOCS3, dilution 1/250 (ob-
tained from Assay Designs), was added to incubate the
specimens for 30 min. A biotinylated, rabbit anti-mouse
secondary antibody (dilution 1/200 [Vector Laborato-
ries]) was also added. The specimens were allowed to
react with preformed avidin-biotin-enzyme complex
(ABC-ELITE reagent [Vector Laboratories]) for 30 min,
followed by incubation with 3-amino-9-ethylcarbazole
substrate for 15 min to develop a staining pattern. Coun-
terstaining was done with Mayer’s hematoxylin. As a
control, irrelevant mouse IgG1 was used.
From the immunohistochemical staining, we found a
higher expression of SOCS3 protein in dendritic cells
and an increased number of SOCS3-positive cells in ep-
idermis from lesional AD skin compared with nonle-
sional AD skin and normal skin from healthy controls
(ﬁg. 2). The altered SOCS3 protein expression in AD
skin and the fact that SOCS3 maps to a region that has
been reported to be linked to AD supported the idea
that SOCS3 might be critically involved in AD and
prompted us to investigate genetic association between
SOCS3 and AD.
We ﬁrst analyzed a set of 406 Swedish families with
at least one sibling affected with AD (1,334 total affected
individuals). The families were recruited at the Derma-
tology Unit, Department of Medicine, Karolinska Uni-
versity Hospital Solna, Stockholm, during 1995–1997.
The patients were all classiﬁed as having AD on the basis
of clinical examination by dermatologists, who applied
the U.K. Working Party’s diagnostic criteria.6 Mean age
was 29 years. Allergen-speciﬁc serum IgE antibodies to
inhalant and food allergens were measured in all siblings
with AD.9 Subjects were classiﬁed as having allergic
asthma or allergic rhinoconjunctivitis on the basis of an
interview. Of these 406 families, 109 were studied in the
previously published genomewide linkage analysis.4
Ten SNPs were selected from the NCBI dbSNP Home
Page from ∼10 kb upstream of the SOCS3 gene and
throughout the gene. SNPs that have been been validated
by several methods according to dbSNP and that had a
minor-allele frequency 15% were chosen with priority.
The SNPs were rs8074003, rs12952093, rs9914196,
rs4969170, rs12949584, rs11868378, C920rA,
rs1061489, rs2280148, and rs4969168. Genotyping
was performed with TaqMan SNP Genotyping Assay
(Applied Biosystems [ABI]). Primers and probes were
obtained from ABI. One allelic TaqMan probe was la-
beled with ﬂuorescent FAM dye, and the other with VIC
dye. PCRs were run in 2# TaqMan Universal PCRMas-
ter Mix and No AmpErase UNG, with primer concen-
trations of 225 nM and probe concentration of 50 nM.
The total reaction volume was 5 ml of 1-ng/ml genomic
DNA. All SNPs were ampliﬁed using TaqMan Universal
PCR protocol (95C for 10 min, followed by 40 cycles
at 92C for 15 s, and 60C for 1 min). The plates were
then placed in the 7900HT Fast Real Time PCR System,
where the ﬂuorescence intensity in each well of the plate
was read using the program SDS 2.2.1. Three of the
genotyped SNPs were not found to be polymorphic
when tested in 380 individuals (rs12949584, C-920rA,
and rs1061489) and a fourth (rs11868378) failed to pass
ABI’s quality control.
Of 10 tested SNPs, 6 were successfully genotyped in
the 3.5-kb SOCS3 gene and in a region ∼10 kb upstream
of the gene (ﬁg. 3). Population Hardy-Weinberg equi-
librium was evaluated for each SNP by use of a x2 test
as implemented in the zGenStat 1.128 software (Henric
Zazzi), with a cutoff value of . Two of the SNPsP 1 .01
were signiﬁcantly associated with the AD phenotype
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Figure 3 Schematic overview of the location and distribution of
the 10 SNPs genotyped in the SOCS3 gene and the LD structure in
the region. Positions relative to the transcription start are indicated.
The four SNPs marked with an asterisk (*) either were not polymor-
phic in the analysis (of 380 individuals) or failed to pass ABI’s quality
control. See main text for details on SNP selection. The number in
each box in the LD plot corresponds to the pairwise LD coefﬁcient
D′ between respective SNPs, calculated using Unphased.10 Block 1
spans from rs8074003 to rs4969170, and block 2 from rs4969170 to
rs4969168.
Table 2
Genetic Association of SOCS3 with AD in Swedish Family Material
ALLELE OR HAPLOTYPE
FREQUENCY
NO. OF
TRANSMISSIONSa
TRANSMISSION
FREQUENCY
(%) Prs12952093 rs4969170 rs4969168
A .31 286 55 .03
A .37 351 54 .02
G .83 761 50 NS
C G .61 1,140 49 .04
A A .32 582 51 .02
C G G .64 1,118 49 NS
A A G .16 389 52 NS
NOTE.—The data shown are from 406 families, including 1,334 individuals with AD. Mean age
was 29 years. Statistical analysis was performed using Unphased,10 with the pdtphase command for
multiplex families. Transmission frequencies were estimated with the program PDT11 for alleles and
with the program Transmit12 for haplotypes. P values were corrected with either the number of tested
SNPs ( ) or the number of tested haplotypes (haplotypes with frequency 15%; ). NS pnp 3 np 4
not signiﬁcant.
a Transmissions to affected individuals.
( for rs12952093; for rs4969170) (tableP ! .03 P ! .02
2). When analyzing the linkage disequilibrium (LD)
structure in the gene, using the program Unphased,10 we
found that all analyzed SNPs fell into two haplotype
blocks. We then identiﬁed three haplotype-tagging SNPs
as representative of these haplotype blocks: rs12952093
and rs4969170 in block 1 and rs4969168 in block 2.
Two of these were in the promoter region of the gene
(rs12952093 and rs4969170), and the third was in the
3′ UTR (rs4969168). One haplotype from the ﬁrst block
was positively associated with AD (A-A; ), andP ! .02
one was negatively associated (C-G; ) (table 2).P ! .04
In addition, the SOCS3 gene was linked to AD in these
families ( ; ) in a nonparametric link-LODp 1.63 P ! .04
age analysis performed using the program Allegro (ex-
ponential model with power weighting of families).13
However, the linkage did not reach the previously re-
ported suggestive linkage level ( ) in chro-4P ! 7.4# 10
mosomal region 17q25, indicating that SOCS3 is not
the only gene contributing to the broad peak in the
region.
To conﬁrm the genetic association, we analyzed the
three haplotype-tagging SNPs in two independent sets
of patients and controls. The ﬁrst was a nested case-
control sample consisting of 555 children from the pop-
ulation-based birth cohort BAMSE, which comprises
4,089 children who were recruited in the Stockholm area
between 1994 and 1996.14–16 When the children were 1,
2, and 4 years old, questionnaires that included ques-
tions on symptoms related to wheezing and allergic dis-
eases were completed. The children with reported symp-
toms of dry skin in combination with itchy rash for at
least 2 wk with typical localization and/or who received
a diagnosis of eczema from a doctor were classiﬁed as
having AD.14 Allergen-speciﬁc serum IgE antibodies to
inhalant and food allergens were measured in all chil-
dren. At 2 and/or 4 years of age, 328 children received
the diagnosis of AD. Children with no reported eczema,
asthma, or allergic rhinoconjunctivitis and with no al-
lergen-speciﬁc IgE were used as healthy controls. Of the
555 total children, 328 were affected with AD and 227
were controls. Mean age was 4.3 years.
The second was a case-control study comprising 187
adult patients with AD (102 females and 85 males) and
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Table 3
Genetic Association of SOCS3 with AD in Two Independent Case-Control Studies
SWEDISH NESTED CASE-CONTROL STUDY U.K. CASE-CONTROL STUDY
ALLELE OR HAPLOTYPE Frequency (%) in
OR (95% CI) P
Frequency (%) in
OR (95% CI) Prs12952093 rs4969170 rs4969168 Controls Patients Controls Patients
A 26 33 1.45 (1.10–1.92) .03 27 26 .95 (.69–1.31) NS
A 31 41 1.51 (1.16–1.97) .009 34 31 .87 (.64–1.18) NS
G 85 84 .90 (.62–1.31) NS 85 90 1.53 (.99–2.36) NS
C G 68 58 .67 (.51–.87) .02 66 68 1.12 (.82–1.53) NS
A A 33 24 1.50 (1.12–2.00) .03 26 25 .94 (.64–1.38) NS
C G G 69 58 .63 (.48–.82) .004 66 69 1.15 (.85–1.56) NS
A A G 15 23 1.72 (1.22–2.43) .01 19 20 1.07 (.70–1.63) NS
NOTE.—Shown are the association results from the Swedish nested case-control study (328 individuals with AD; 227 controls; mean age
4.3 years) and from the U.K. case-control study (187 individuals with AD; 230 controls; mean age 45 years). Statistical analysis was performed
using Unphased,10 with the cocaphase command for case-control studies. The signiﬁcance of associations of individual haplotypes in the case-
control studies was estimated using standard x2 tests. P values have been corrected with either the number of tested SNPs ( ) or thenp 3
number of tested haplotypes (haplotypes with frequency 15%; ). NS p not signiﬁcant.np 4
230 age- and sex-matched controls (162 females and 68
males) from the United Kingdom.17 For all patients, AD
was diagnosed by a dermatologist using the standard
clinical criteria of Haniﬁn and Rajka.18 The minimum
age at study was 18 years, and the mean age was 45
years. Total serum IgE levels were elevated in 127 of the
patients with AD, and 164 had other atopic manifes-
tations. The controls did not have AD but were not
checked for IgE levels or other atopic manifestations.
When analyzing the Swedish case-control samples, we
found a highly signiﬁcant genetic association between
AD and both the positively associated haplotype (P !
) and the negatively associated haplotype ( ).03 P ! .02
(table 3). However, we could not conﬁrm these associ-
ations in the U.K. study (table 3). The power to detect
association for the two associated haplotypes in the U.K.
study was 83% for the negatively associated haplotype
( ; odds ratio [OR] 0.62) and 80% for the posi-P ! .05
tively associated haplotype ( ; OR 1.72), with theP ! .05
assumption of the same haplotype frequencies as ob-
served in the Swedish case-control study. Power analysis
was performed using the PS software,19 version 2.1.31.
The lack of association in the U.K. study could be
because of differences between the two populations in
the relative contribution of SOCS3 as a genetic risk fac-
tor. Another potential explanation for the discrepancy
is that the importance of SOCS3 as a risk factor might
be age dependent, since the most signiﬁcant association
of SOCS3 was seen in children with AD. It is also pos-
sible that the selection of controls in the U.K. study in-
ﬂuenced the results. Controls in the U.K. study were not
checked for other atopic manifestations as they were in
the Swedish case-control study, which is a limitation be-
cause the potential role of SOCS3 in other atopic man-
ifestations is unknown.8 However, in a meta-analysis20
of the two case-control sets, the risk haplotype was sig-
niﬁcantly associated ( ; combined OR 1.37; 95%P ! .02
CI 1.07–1.77) and a test of heterogeneity between the
studies was not signiﬁcant. The meta-analysis was per-
formed in accordance with the method of Woolf.20
The consistently elevated expression of SOCS3 in skin
of patients with AD, together with evidence for genetic
association in two independent patient data sets, makes
SOCS3 a strong candidate gene for AD susceptibility.
This evidence is reinforced by the potential pathophys-
iological link between the activity of SOCS3 and the
pathogenesis of AD. SOCS3 is an SH2-containing pro-
tein that binds to the activation loop of Janus kinases,
inhibiting kinase activity and thereby suppressing cy-
tokine signaling. The promoter of the SOCS3 gene con-
tains two STAT-responsive elements and one GC-rich
element.21 SOCS3 is expressed predominantly in T-
helper type 2 (TH2) cells and has an important role in
regulating the onset and maintenance of TH2-mediated
responses.8 Patients with AD have increased numbers of
TH2-expressing cells in peripheral blood and elevated
interleukin-13 expression in the skin, which indicates
a systemic TH2 environment.
22 Socs3 transgenic mice
showed increased TH2 responses.
8 These mice, consti-
tutively expressing the Socs3 protein, had about two-to-
three times higher expression of Myc-tagged Socs3 than
of endogenous Socs3 in TH2 cells. However, the presence
or absence of AD-like features in the Socs3 transgenic
mice and the expression of Socs3 protein in cell types
other than T cells were not reported. In contrast, dom-
inant-negative mutant Socs3 transgenic mice and mice
with a heterozygous deletion of Socs3 had decreased TH2
development.8 Despite the connection between SOCS3
and AD, it is still unclear how the polymorphisms in the
SOCS3 gene might affect development of AD, but there
may be a direct effect on SOCS3 transcription, since two
of the associated SNPs are located in predicted tran-
scription-factor binding sites (RAVEN).
In conclusion, we found that SOCS3 is consistently
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more highly expressed in skin from patients with AD
than in normal control skin and that speciﬁc haplotypes
of the SOCS3 gene are signiﬁcantly associated with the
disease. We suggest that SOCS3 may play an important
role in AD pathogenesis, at least for a Swedish popu-
lation with AD. We also suggest that SOCS3 and the
pathways that it regulates may be important targets for
future investigations of the molecular pathogenesis of
AD and for therapeutic developments.
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